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and convenient way for early detection of human disease. However,
many approaches to identify HCC biomarkers are based on NGS
(next generation sequencing) technology (Li and Mao, 2013),
which is costly and time-consuming. In a study published in this
issue of EBioMedicine, Watanabe et al. (2016-in this issue) demon-
strated that the serum level of TGF-β1 negatively correlates withHepatocellular carcinoma (HCC) is a type of liver cancer, causing the
highestmortality in theworld (Hong et al., 2015). Although surgical op-
eration or other intervention therapies are effective at an early stage of
HCC, up to 70% of these early stage patients will develop to recurrent tu-
mors within ﬁve years (Hong et al., 2015), suggesting that it is quite im-
portant to establish a promising biomarker for early diagnosis of the
development of HCC.
Although considerable progress has been made in HCC biomarkers
discovery, very few biomarkers have exhibited promising clinical out-
come. AFP (alpha-fetoprotein), is currently being considered as a well-
established biomarker for HCC, but the positive predictive value is esti-
mated less than 33% (Chen et al., 2003). Furthermore, the association of
AFP with ultrasonography only improved the sensitivity by around 7%
and the speciﬁcity by only 2% compared to applying ultrasonography
alone, while increasing the cost of the screening (Zhang and Yang,
1999). In addition, not only less than 20% (10–20%) portion of early
stage tumors present with abnormal AFP serum levels (European
Association for Study of Liver., 2012), but also high serum AFP level in
cirrhosis patients could be caused byHBV or HCV infection, or exacerba-
tion of other underlying liver diseases other thanHCC (Di Bisceglie et al.,
2005). These information above clearly demonstrated that AFP may not
be a ideal biomarker for HCC diagnosis. The otherbiomarkers, such as
DCP (des-γ-carboxy prothrombin), GPC3 (glypican-3), and GP73
(Golgi protein 73) (Yamamoto et al., 2010), have been proposed as
early biomarkers for HCC, cannot stand for a criteria to assess the devel-
opment of HCC. To date, none of these molecules are promising in
predicting the risk of HCC occurrence and no effective systemic bio-
markers have been established.m.2016.09.001.
er for Translational Medicine,
al Physics, Chinese Academy of
. This is an open access article underPredicting cancer occurrence by simple blood testing is most rapid
HCC occurrence, suggesting the potential of TGF-β1 as a novel bio-
marker for HCC early detection v. TGF-β1 is one of three members
of the transforming growth factor β superfamily of cytokines. It is a
secreted protein involved in a number of cellular functions, including
cell proliferation, cell growth, differentiation and apoptosis. Meindl-
Beinker group revealed that TGF-β1 may function as a tumor
suppressor at early stages of liver damage, whereas TGF-β1 may
promote tumor associated phenotype rat cancer early stages
(Meindl-Beinker et al., 2012). Moreover they also showed that
TGF-β1 could function as a molecular switch of the pathway from
cytostatic to tumor promoting in survival signaling pathways in
hepatocytes. These ﬁndings suggest TGF-β1 be a novel therapeutic
target for inhibition of liver disease progression (Meindl-Beinker et
al., 2012).
In this present study, a nested case-controlled (NCC) study was
employed as the statistics method (Watanabe Y et al., 2016-in this
issue). Different from a case-control study, only a subset of controls
from the cohort is compared to the incident cases in a NCC study
(Cai and Zheng, 2012). In this NCC study, factors such as HCV infec-
tion were matched to selecting controls from relevant risk sets,
which could be more efﬁcient and reliable than a case control study
with the same number of controls. Since little is known about the re-
lationship between TGF-β1 related pathway and HCV-positive HCC,
further study may be required to show the role of TGF-β1 in these in-
dividuals. Furthermore, an alternative interpretation for the de-
creased serum level of TGF-β1 is the enhanced uptake of TGF-β1 by
liver tissue. Increase of cellular TGF-β1 may signiﬁcantly contribute
to the pathogenesis of HCC, thus, the intracellular level of TGF-β1
and pathological analysis in liver tissues may be of importance to
be investigated in the future.
In conclusion, the study byWatanabe et al. (2016-in this issue) may
open an interesting perspective of predicting biomarker and provides
option for a diagnostic approach fromblood samples of HCC. Theseﬁnd-
ing would potentially contribute to improvement in prediction and
early detection of HCC development.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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